Duxi Zheng

Duxi Zhang has been involved in Tri-state CACS planning activities since 2006 and was elected president in 2009. He holds a PhD degree in Analytical Chemistry from Purdue University and a MS degree in organic analysis from Shandong University. He works as a Senior Research Investigator in the Bioanalytical Sciences department within Bristol‑Myers Squibb R&D in its Princeton research facility. During his time in BMS, he led the bioanalysis support for NDA approval of entecavir (BaracludeÔ), a novel treatment for hepatitis B. He currently leads a team of scientists supporting BMS development projects in infectious disease, oncology, cardiovascular and neuroscience areas. He is a member of ACS, ASMS, and AAPS and a regular reviewer of Journal of Chromatography B. Outside his work, he is actively involved in local scientific communities. He served on the board of NJACS Mass Spectrometry Discussion Group from 2003 to 2007 and was the Chair for 2007. In his spare time, he also coaches kids soccer and enjoys playing volleyball.